Structural Heart & Rhythm Devices: Partners in Pharmacotherapy

Mitral Regurgitation & The Virtuous Cycle: Dr. Isaac Pascual opens by addressing the undertreatment of Functional Mitral Regurgitation (FMR). He challenges the dichotomy between the COAPT and MITRA-FR trials, proposing that they are complementary rather than contradictory. He introduces the concept of a "virtuous cycle" where Edge-to-Edge (H2H) repair stabilizes the patient enough to tolerate higher doses of neurohormonal blockade, effectively turning a mechanical intervention into a pharmacological enabler.

TAVI: The New Age Threshold: Dr. Raquel del Valle breaks down the brand-new ESC Guidelines (released just a month prior), which have lowered the age threshold for TAVI to 70 years. She discusses the critical shift toward "lifetime management," analyzing why bicuspid valves remain a challenge and why the durability of the first device determines the strategy for the second.

Resynchronization (CRT): Dr. Fabian Fastenrath presents Cardiac Resynchronization Therapy (CRT) not as a competitor to drugs, but as the solution to the "Four Horsemen of Missed Target Dosage" (hypotension, bradycardia, kidney failure, and hyperkalemia). He explains how correcting electrical dyssynchrony improves hemodynamics enough to allow physicians to stop "benching their star players" (optimal medical therapy).

The Evolution of Stents: Finally, Dr. Marcel Almendarez takes the audience from the era of plain balloons to the future of nanotechnology. He debates the "leave nothing behind" strategy using Drug-Coated Balloons (DCB)—specifically new Sirolimus-eluting options—and explores how precision stents tailored to a patient's immunology could end the cycle of chronic inflammation and restenosis.

Why watch: This session is vital for understanding how to time interventions to maximize the efficacy of your pharmacological treatment, ensuring you don't wait until the "end-stage" to intervene.